214 related articles for article (PubMed ID: 31361303)
1. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
[TBL] [Abstract][Full Text] [Related]
2. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
3. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
4. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
6. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
8. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
10. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
11. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
12. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
13. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
14. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
16. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
[TBL] [Abstract][Full Text] [Related]
17. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
18. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
19. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
[TBL] [Abstract][Full Text] [Related]
20. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]